

Frequency of S447X lipoprotein lipase and -514C>T hepatic lipase gene polymorphism amongst Indian sickle cell patients

S.Pandey^{1*}, R.Saxena¹, R.M.Mishra², U.K.Chauhan³, M.Sharma⁴, Sw.Pandey³

¹Dept of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, (INDIA)

²Dept of Environmental Biology, APS University, Rewa - 486003, (INDIA)

³Centre for Biotechnology Studies, APS University, Rewa - 486003, (INDIA)

⁴Dept of Hematology, Safdarjung Hospital, Ansari Nagar, New Delhi - 110029, (INDIA)

E-mail: pandeysanjaybt@rediffmail.com

Received: 15th June, 2013 ; Accepted: 31st August, 2013

ABSTRACT

Study states the lipoprotein lipase and hepatic lipase gene polymorphism may be associated in cardio vascular disease. Thus our aim was to evaluate the frequency of LPL and HL polymorphism in Indian sickle cell patients and their clinical outcomes. We had evaluated 162 sickle patients and 170 controls to compare the frequency. Study reported the similar frequency amongst patients and controls. Their was no clinical association of these gene variant and cardiac risk factor in sickle patients.

! 2013 Trade Science Inc. - INDIA

KEYWORDS

LPL;
HL;
SCD;
Polymorphism.

INTRODUCTION

Lipoprotein lipase is a glycoprotein enzyme that plays a key role in hydrolyzing triglycerides in chylomicrons and very low density lipoproteins (VLDL) as the first step in their metabolism^[1,2]. Human PHP-LPL is catalytically active in a monomeric form, and its apparent molecular weight is 61,000^[3], whereas there is a report that human LPL is catalytically active in a dimeric form^[4]. Major cause of morbidity and mortality accounts coronary artery disease. Recent research indicate the alterations in lipid metabolism, including high LDL (low density lipoprotein) and low HDL (high density lipoprotein) cholesterol, high triglycerides levels, high apoB levels, high lipoprotein (a) (Lp (a) levels, are all important risk factors for CAD. All these

lipid abnormalities themselves have genetic determinants^[5,6]. Hepatic lipase (HL) is a lipolytic enzyme that contributes to the regulation of plasma triglyceride (TG) levels and synthesized by hepatocytes and found localized at the surface of liver sinusoid capillaries. Increased levels of TG may increase the risk of developing coronary heart disease, and studies suggest that mutations in the HL gene may be associated with elevated TG levels and increased risk of coronary heart disease. It is secreted and bound to the hepatocyte surface and readily released by heparin. It is a member of the lipase super family and is homologous to lipoprotein lipase and pancreatic lipase^[7-9]. There is a paucity of data of these variants. In this study, the frequency of these mutations was assessed in Asian Indian origin SCD patients.

MATERIALS AND METHOD

Subjects were sickle cell patients who attended the out patients department; All India Institute of Medical Sciences (AIIMS), New Delhi, India. This study was done in the Department of Hematology and it was approved by the institutional ethical committee. About 5 ml blood sample was collected from the patients after taken their informed consent. The complete blood count and the red cell indices were measured by an automated cell analyzer (SYSMEX K-4500, Kobe Japan). The quantitative assessment of Hb F, Hb A, Hb A2 and Hb S and the diagnosis of the sickle homozygous and the sickle beta thalassaemia patients was done by high performance liquid chromatography (HPLC-Bio-Rad-Variant TMBio Rad, CA, USA). DNA extraction was performed by the phenol-chloroform method. Genotyping of S447X and -514C>T was done according to published literatures^[10,11]. Statistical analysis was performed using GraphPad statistics software. Yates chi-square test was used to assess the intergroup significance. A p-value of <0.05 was considered as statistically significant.

RESULT AND DISCUSSION

Study subjects were sickle cell patients [SA,45; SS,50; SB,70 (mean age 15.25±1.8 years)] while 170 age and sex match controls were recruited to compare the frequency. Out of 162 Sicklers 136 were normal for LPL and 26 carry mutations while 117 SCD patient were normal for HL variant and 40 were carry mutation. P-value was not statistically significant. Details of

sub groups of sicklers and controls frequency is illustrated in TABLE 1. Lipoprotein levels are partly determined by genes that code for proteins that regulate lipoprotein synthesis. Mutations in these genes may cause disturbances in one or more of the pathways in lipoprotein metabolism resulting in hyper lipoproteinemia, and some of these disorders lead to premature atherosclerosis. All lipid abnormalities have genetic determinants. A study conducted in Italian population with genetic variables *apolipoprotein E (Apo E)*, *Apo AI*, *Apo CIII*, *Apo B*, *lipoprotein lipase (LPL)* and the *hepatic lipase (LIPC)* genes and concluded the variation in *LIPC (hepatic lipase) gene* associates with clinical outcomes in Italian patients with established CAD^[12]. A study and concise review reported the significant presence of hepatic lipase -514C>T polymorphism in Indians^[11]. Another study also reported the S447X Polymorphism and hepatic lipase (*LIPC*) association with lipid variations^[13,14]. In our study we had reported the frequency of S447X and -514C>T polymorphism in sickle cell patients, however these variant also present in healthy individuals. Earlier studies in Europeans have identified small dense LDL to be associated with coronary artery disease and diabetes. An Indian study resulted in association of small dense LDL with diabetes and CAD in Asian Indians^[15]. HTG is considered as a risk factor for CAD in Asian Indians, there is an urgent need to evaluate the association of *APOC3* SstI polymorphism with the risk of developing coronary artery disease in Asian Indians^[16]. Low serum cholesterol and other lipoprotein levels in SCD patients is consistent with other reports both in Nigeria and elsewhere. It is important to mention that the levels in Nigerian adult

TABLE 1 : Comparative frequency of LPL and HL variants in sicklers and controls

Mutation	Genotype	Patients			Control N=170	p-value	OR	95%CI
		SA N=45	SS N=50	Sβ N=67				
LPL (S447X)	-/-	37(82.22%)	43(86%)		148(87.05%)	0.516	0.78	0.40-1.50
	+/-	56(83.58%)			18(10.588%)	0.405	1.40	0.69-2.84
	+/+	8(17.77%)	6(12%)		4(2.35%)	0.948	0.78	0.14-4.21
		9(13.43%) 0(0)	1(2%)	2(2.98%)				
HL (-514C>T)	-/-	34(75.55%)	34(68.0%)		133(78.23%)	0.509	0.81	0.47-1.40
	+/-	49(73.13%)			27(15.882%)	0.290	1.41	0.77-2.57
	+/+	9(20%)	9(18.0%)		10 (5.882%)	0.741	0.75	0.25-2.20
		15(22.38%) 2 (4.444%)	2(4.0%)	3(4.477%)				

Regular Paper

sickle cell disease patients is much more lower compared with the lipid levels reported in both African American and Saudi Arabian patients with SCD. Lipid metabolism in SCD appears to be different from that in sickle cell trait and normal haemoglobin in adult Nigerian SCD patients. The exact cause is not known but appears to be multifactorial^[17-22]. In our cases the frequency of LPL and HL variant was similar and statistically not significant. So the study concludes there was no correlation of these lipid variants and cardiac clinical outcomes in Indian sickle cell patients.

ACKNOWLEDGEMENTS

Sincere thanks to technical staff of department of hematology AIIMS, for expert assistance. This study Financial supported by ICMR & Hematology Department AIIMS, New Delhi.

REFERENCES

- [1] P.Nilsson-Ehle, A.S.Garfinkel, M.C.Schotz; Lipolytic enzymes and plasma lipoprotein metabolism. *Annu.Rev.Biochem.*, **49**, 667-693 (1980).
- [2] L.C.Smith, H.J.Pownall; Lipoprotein lipase. In Lipase. B.Borgstrom, H.L.Brockman, (Eds); Elsevier, Amsterdam, 263-305 (1984).
- [3] Y.Ikeda, A.Takagi, A.Yamamoto; Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma: Production of monospecific antibody to the individual lipase. *Biochim.Biophys. Acta*, **1003**, 254-269 (1989).
- [4] J.Peterson, W.Y.Fujimoto, J.D.Bmzell; Human lipoprotein lipase: Relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies. *J.Lipid.Res.*, **33**, 1165-1170 (1992).
- [5] D.J.Galton; Lipids and cardiovascular disease. *Br.Med.Bull.*, **46**, 865-1090 (1990).
- [6] K.Sankaranarayanan, R.Chakraborty, E.A.Boerwinkle; Ionizing radiation and genetic risks VI. Chronic multifactorial diseases: A review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus. *Mutation Research*, **436**, 21-57 (1999).
- [7] Cynthia Chatterjee, Daniel L.Sparks, Hepatic lipase, high density lipoproteins, and hypertriglyceridemia. *Am.J.Pathol.*, **178**(4), 1429-1433 (2011).
- [8] P.W.Connelly, R.A.Hegele; Hepatic lipase deficiency. *Crit.Rev.Clin.Lab.Sci.*, **35**(6), 547-72 (1998).
- [9] B.Perret, L.Mabile, L.Martinez, F.Tercé, R.Barbaras, X.Collet; Hepatic lipase: Structure/function relationship, synthesis, and regulation. *J.Lipid.Res.*, **43**(8), 1163-9 (2002).
- [10] B.E.Groenemeijer, M.D.Hallman, P.W.Reymer, E.Cagne, J.A.Kuivenhoven, T.Bruin, et al.; Genetic variant showing a positive interaction with beta blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglycerides levels in coronary artery disease patients. The Ser447Stop substitution in the lipoprotein lipase gene. Regress study group. *Circulation*, **95**, 2628-35 (1997).
- [11] E.Shyong Tai, Dolores Corella, Mabel Deurenberg-Yap, Jeffery Cutter, Suok Kai Chew, Chee Eng et al.; Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: The 1998 Singapore National Health Survey. *J.Nutr.*, **133**, 3399-3408 (2003).
- [12] Marco G.Baroni, Andrea Berni, Stefano Romeo, Marcello Arca, Tullio Tesorio, Giovanni Sorropago, Umberto Di Mario, David J.Galton; Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): Variation in LIPC gene associates with clinical outcomes in patients with established CAD. *BMC Medical Genetics*, **4**(8), 1-7 (2003).
- [13] Katia A.Almeida, Célia M.C.Strunz, Raul C.Maranhão, Antonio P.Mansur; The S447X polymorphism of lipoprotein lipase: Effect on the incidence of premature coronary disease and on plasma lipids. *Arq.Bras.Cardiol.*, **88**(3), 267-273 (2007).
- [14] Rudy Guerra, Jinping Wang, Scott M.Grundy, Jonathan C.Cohen; A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. *Proc.Natl.Acad.Sci.*, **94**, 4532-4537 (1997).
- [15] V.Mohan, R.Deepa, K.Velmurugan, K.Gokulakrishnan; Association of small dense LDL with coronary artery disease and diabetes in urban Asian Indians - the Chennai Urban Rural Epidemiology Study (CURES-8). *J.Assoc.Physicians India*, **53**, 95-100 (2005).
- [16] S.Chhabra, R.Narang, L.R.Krishnan, S.Vasisht, D.P.Agarwa, L.M.Srivastava, S.C.Manchanda, N.Das; Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. *BMC Genetics*, **3**, 9 (2002).

- [17] P.A.Akinyaju, C.O.Akinyaju; Plasma and red cell lipids in sickle cell disease. *Annals.Clin.Lab.Sci.*, **6(6)**, 521-524 (1976).
- [18] R.R.Elmehdawi; Hypolipidemia: A word of caution. *Libyan J.Med.*, **3(4)**, 84-90 (2008).
- [19] I.A.O.Oforofuo, M.O.Adedeji; Effect of sickle cell gene expression in plasma cholesterol in a Nigerian population. *Clin.Biochem.*, **27**, 505-508 (1994).
- [20] Z.Rahimi, A.Merat, M.Haghshenass, H.Madani, M.Rezeal, R.L.Nagel; Plasma lipids in Iranians with sickle cell disease: Hypocholesterolemia in sickle cell anaemia and increase of HDL cholesterol in sickle cell trait. *Clin.Chimica Acta*, **365(1-2)**, 217-220 (2006).
- [21] M.Z.Zailare, Z.M.Marzouki, S.M.Khoja; Plasma and red blood cell membrane lipid concentration of sickle patients, *Saudi Med.J.*, **24(4)**, 376-379 (2003).
- [22] M.A.Emokpae, P.O.Uadia, Osadolor, H.B.Lecithin; Cholesterol acyltransferase, lipoprotein lipase and lipoproteins in adult Nigerians with sickle cell disease. *African Journal of Biochemistry Research*, **4(2)**, 17-20 (2010).